Japan Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online provi

Japan Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Opportunity Analysis and Industry Forecast, 2023-2032


The Japan myasthenia gravis treatment market is anticipated to witness considerable growth during the forecast period. Myasthenia gravis is an autoimmune neuromuscular disorder which is triggered by defect in neuromuscular transmission. The autoimmune disorder is very responsive to treatment, and the symptoms are constantly coming to be extra efficient. The treatments of myasthenia Gravis are needed for improving the health condition of individuals, and the quality of life.

Rise in prevalence of myasthenia gravis and increase in awareness regarding treatments of the disorder is a significant factor driving the growth of the Japan myasthenia gravis treatment market. Furthermore, with improved medical diagnosis, there is surge in need for advanced treatment options, which is expected to augment the growth of the market. In addition, the advent of monoclonal antibodies, combined with the different benefits related to them, such as high selectivity and long-lasting activity, is expected to provide profitable opportunities during the projection duration.

Furthermore, rise in financial investments by the pharmaceutical companies in R&D activities are anticipated to spur the need for myasthenia gravis disorder medicines in the Japan myasthenia gravis treatment market.

On the other hand, side effects of the drugs used for dealing with myasthenia gravis and lack of technical skilled expertise are expected to hamper the market growth.

Conversely, the authorization of license for new treatment options for myasthenia gravis is expected to offer lucrative opportunities for the growth of the Japan myasthenia gravis treatment market. For instance, in 2017, the united state FDA granted AbbVie's new drug application (NDA) for Rituxan (rituximab) as an intravenous (IV) infusion 100 mg plus glucocorticoid, for the treatment of adult patients with moderately to severely active myasthenia gravis (MG).

The Japan myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. Monoclonal antibodies (MABs) are medications that are designed to engage specifically with certain kinds of cells, which can be beneficial in treating autoimmune disorders, such as myasthenia gravis. Intravenous immunoglobulin (IVIG) treatment is just one of the most usual treatments for dealing with myasthenia gravis. By age group, the market is divided into below 55 years and above 55 years. The above 55 years segment has a higher frequency of myasthenia gravis, as the disease is more probable to affect older people. Depending on distribution channel, the market is classified into hospital pharmacies, drug stores and retail pharmacies and online providers.

The Porter's five force analysis is a model, which analyzes the competitive scenario of the industry and role of each stakeholder. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of substitutes, the threat of new entrants, and the competition among competitive rivalry.

The threat of new entrants is low due to the existence of patent legislation and the existence of major players in the market. The threat of substitutes is low due to the accessibility of a minimal number of treatments available in the market. The bargaining power of suppliers is low due to the presence of a limited number of suppliers in the market. The bargaining power of buyers is low due to the limited availability of treatment options. The intensity of competitive rivalry is high due to the several significant players in the market.

 The Japan myasthenia gravis treatment market is characterized by the increase in R&D activities by the pharmaceutical business looking to establish new alternatives treatments for the condition. In addition, upsurge in patent issuances for the treatments of myasthenia gravis is fueling the growth of the market.

Key players included in the report are Astellas Pharma, GlaxoSmithKline, Takeda Pharmaceutical, Daiichi Sankyo, Teva Pharmaceutical Industries, Torii Pharmaceutical, UCB, Merck & Co., Pfizer, Genzyme Corporation

The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Japan  Myasthenia Gravis Treatment Market.

Assess and rank the top factors that are expected to affect the growth of japan Myasthenia Gravis Treatment Market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Japan  Myasthenia Gravis Treatment Market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Age group

Below 55 years
Above 55 years

By Drug class

Monoclonal antibodies
Intravenous immunoglobulin
Others

By Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

Key Market Players

Astellas Pharma
GlaxoSmithKline
Takeda Pharmaceutical
Daiichi Sankyo
Teva Pharmaceutical Industries
Torii Pharmaceutical
UCB
Merck & Co.
Pfizer
Genzyme Corporation

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 


CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size and Forecast, By Drug class
4.2. Monoclonal antibodies
4.3. Intravenous immunoglobulin
4.4. Others
CHAPTER 5: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market Size and Forecast, By Age group
5.2. Below 55 years
5.3. Above 55 years
CHAPTER 6: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market Size and Forecast, By Distribution channel
6.2. Hospital pharmacies
6.3. Drug store and retail pharmacies
6.4. Online providers
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Company 1
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Company 2
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Company 3
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Company 4
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Company 5
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Company 6
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Company 7
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Company 8
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Company 9
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Company 10
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 03. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. COMPANY 1: KEY EXECUTIVES
TABLE 05. COMPANY 1: COMPANY SNAPSHOT
TABLE 06. COMPANY 1: OPERATING SEGMENTS
TABLE 07. COMPANY 1: PRODUCT PORTFOLIO
TABLE 08. COMPANY 1: KEY STRATERGIES
TABLE 09. COMPANY 2: KEY EXECUTIVES
TABLE 10. COMPANY 2: COMPANY SNAPSHOT
TABLE 11. COMPANY 2: OPERATING SEGMENTS
TABLE 12. COMPANY 2: PRODUCT PORTFOLIO
TABLE 13. COMPANY 2: KEY STRATERGIES
TABLE 14. COMPANY 3: KEY EXECUTIVES
TABLE 15. COMPANY 3: COMPANY SNAPSHOT
TABLE 16. COMPANY 3: OPERATING SEGMENTS
TABLE 17. COMPANY 3: PRODUCT PORTFOLIO
TABLE 18. COMPANY 3: KEY STRATERGIES
TABLE 19. COMPANY 4: KEY EXECUTIVES
TABLE 20. COMPANY 4: COMPANY SNAPSHOT
TABLE 21. COMPANY 4: OPERATING SEGMENTS
TABLE 22. COMPANY 4: PRODUCT PORTFOLIO
TABLE 23. COMPANY 4: KEY STRATERGIES
TABLE 24. COMPANY 5: KEY EXECUTIVES
TABLE 25. COMPANY 5: COMPANY SNAPSHOT
TABLE 26. COMPANY 5: OPERATING SEGMENTS
TABLE 27. COMPANY 5: PRODUCT PORTFOLIO
TABLE 28. COMPANY 5: KEY STRATERGIES
TABLE 29. COMPANY 6: KEY EXECUTIVES
TABLE 30. COMPANY 6: COMPANY SNAPSHOT
TABLE 31. COMPANY 6: OPERATING SEGMENTS
TABLE 32. COMPANY 6: PRODUCT PORTFOLIO
TABLE 33. COMPANY 6: KEY STRATERGIES
TABLE 34. COMPANY 7: KEY EXECUTIVES
TABLE 35. COMPANY 7: COMPANY SNAPSHOT
TABLE 36. COMPANY 7: OPERATING SEGMENTS
TABLE 37. COMPANY 7: PRODUCT PORTFOLIO
TABLE 38. COMPANY 7: KEY STRATERGIES
TABLE 39. COMPANY 8: KEY EXECUTIVES
TABLE 40. COMPANY 8: COMPANY SNAPSHOT
TABLE 41. COMPANY 8: OPERATING SEGMENTS
TABLE 42. COMPANY 8: PRODUCT PORTFOLIO
TABLE 43. COMPANY 8: KEY STRATERGIES
TABLE 44. COMPANY 9: KEY EXECUTIVES
TABLE 45. COMPANY 9: COMPANY SNAPSHOT
TABLE 46. COMPANY 9: OPERATING SEGMENTS
TABLE 47. COMPANY 9: PRODUCT PORTFOLIO
TABLE 48. COMPANY 9: KEY STRATERGIES
TABLE 49. COMPANY 10: KEY EXECUTIVES
TABLE 50. COMPANY 10: COMPANY SNAPSHOT
TABLE 51. COMPANY 10: OPERATING SEGMENTS
TABLE 52. COMPANY 10: PRODUCT PORTFOLIO
TABLE 53. COMPANY 10: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN JAPAN MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 10. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)
FIGURE 11. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)
FIGURE 12. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
FIGURE 21. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
FIGURE 24. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
FIGURE 27. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
FIGURE 30. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
FIGURE 33. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
FIGURE 36. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
FIGURE 39. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
FIGURE 42. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
FIGURE 45. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
FIGURE 48. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings